Datroway

Oncology

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

News

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

News

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.

News

Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.

News

AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

News

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.